PD-L1 Biomarker Testing Market will reach a value of USD 1.46 Bn by 2032 at a CAGR of 9.4%
The global PD-L1 biomarker testing market size was valued at US$ 541.6 Mn in 2021 and is expected to exhibit a CAGR of close to 9.4% over the forecast period (2022-2032).
Increasing incidence of cancer across the globe is underpinning the need for advanced cancer diagnosis equipment, which is expected to boost the market in the forthcoming years. Cancer immunotherapy is emerging as a new avenue for the development of biomarker testing, thereby augmenting the growth in the market.
Rising technological advancements in immunotherapy are propelling the adoption PD-L1 biomarker testing for non-small cell lung cancer as an effective means for therapeutic usage of PD-L1 proteins for benign lesions or tumor identification.
Moreover, the unmet needs of cancer treatments are addressed by the growing availability of high-quality immunotherapy products worldwide. Lifestyle changes, such as physical inactivity, tobacco consumption and smoking, as well as unhealthy diet are prime factors responsible for the growing burden of cancerous indications in the current scenario.
The emergence of cancer immunotherapy has advanced the diagnostic approach to cancer detection and management, thus propelling the growth in the PD-L1 biomarker testing market.
Key players operating in the market space are focusing on the development or extension of novel biologics using existing biologic resources for innovative product identification and provision of patented therapies.
Furthermore, the occurrence of adverse conditions such as organ failure and relapse into cancer through the process of chemotherapy is anticipated to fuel the adoption of PD-L1 biomarker testing among major healthcare facilities worldwide.
“Growing advancements in the field of oncology, along with accurate prediction insights offered by automated systems for biomarker testing will boost the sales of PD-L1 biomarker testing in the forthcoming years” says an FMI analyst.
Request Sample Report:
- Based on product, PD-L1 22C3 assay kits segment is projected to account for over 53% of the market share by 2032, with sales increasing at a 10.2% CAGR over the forecast period.
- In terms of indication, the NSCLS segment held 61.9% of the total market share in 2021, and the trend is expected to continue over the assessment period.
- By end user, sales in the cancer research institutes segment accounted for 43.2% of the total market share in 2021.
North America is slated to be the largest leading region with a value share of over 61%, spearheaded by the U.S.
- Sales in the U.K. will increase at a 10% CAGR over the assessment period.
- China will emerge as a lucrative market, with demand growing at a 10.9% CAGR over the forecast period.
Leading players operating in the market are actively working in coherence with researchers to be able to acquire enhanced and innovative concepts to widen the therapeutic actions of the product. For instance:
- In May 2020, F. Hoffman-La Roche AG acquired Stratos Genomics to develop DNA-based sequencing for diagnostic use.
- In July 2020, Abcam plc. and Cancer Research UK partnered for the development and commercialization of novel antibodies to accelerate cancer research.
Want more insights?
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global PD-L1 biomarker testing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on PD-L1 biomarker testing market segment based on product (PD-L1 22C3 assay kit, PD-L1 28-8 assay kit, PD-L1 SP142 assay kit and PD-L1 263 assay kit), indication (NSCLS, melanoma, renal cell carcinoma, gastrointestinal tract malignancy, haematological malignancies, ovarian cancer and others), end user (hospitals, diagnostic laboratories and cancer research institutes) across seven major regions.
About Healthcare Division at Future Market Insights
Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here.
Ask for Customization:
Key Market Segments Covered In PD-L1 Biomarker Testing Industry Research
- PD-L1 22C3 Assay Kit
- PD-L1 28-8 Assay Kit
- PD-L1 SP142 Assay Kit
- PD-L1 263 Assay Kit
- Renal Cell Carcinoma
- Gastrointestinal tract Malignancy
- Haematological Malignancies
- Ovarian Cancer
By End User:
- Diagnostic Laboratories
- Cancer Research Institutes
- North America
- Latin America
- South Asia
- East Asia
- Middle East and Africa (MEA)
Get In Touch With Our Team For 20% Flat Discount:
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA